What is behind Pfizer stock's recent drop in value today

Traders Union
All News
Financial News
Pfizer slides 3.41% today to $26.88

Highlights

Pfizer finalized its exit from ViiV Healthcare for $1.875 billion, with Shionogi raising its stake and GSK maintaining control.
The company will close its South San Francisco R&D site, highlighting persistent difficulties in the Bay Area biotech industry.
Technicals indicate short- and medium-term selling pressure, but consolidation is expected between $26.76 and $27.12, with potential for an upward breakout.

Asset sales and research cuts reinforce negative market sentiment

Pfizer completed its exit from ViiV Healthcare, receiving $1.875 billion as Shionogi increased its stake while GSK retained majority control. The company also announced plans to close its South San Francisco research site by the end of April, reflecting ongoing challenges in the Bay Area's biotech sector. Pfizer continued involvement in the development of treatments for Parkinson’s Disease was noted in a recent industry analysis, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, views Pfizer’s technical structure as broadly weak in the near term, despite long-term support above its 200-day average. He notes that ongoing news — such as the ViiV Healthcare exit and Bay Area research site closure — underscore persistent sector and operational headwinds. Momentum readings remain inconclusive. Kharitonov highlights the dominant intraday selling and overbought signals as further risks. "Short- and medium-term sentiment for Pfizer stays under pressure, and I see little reason for optimism until technical or fundamental catalysts shift hard to the upside."

Viktoras Karapetjanc, expert at Traders Union, sees strong potential for a rebound supported by favorable technicals and persistent institutional activity. He views Pfizer’s cash influx from the ViiV Healthcare transaction as bolstering strategic flexibility, while long-term participation in Parkinson’s therapies adds to growth drivers. The bullish structure remains intact above the 200-day moving average. "Weekly indicators point to further upside, and I expect the market to offer multiple attractive setups around the $27.12 level."

Mixed momentum as intraday sellers test long-term support

Pfizer is trading below its 20-day and 50-day Moving Averages at $26.88 (MA-20: $27.33, MA-50: $27.04), but holds above its 200-day Moving Average at $25.48. This setup signals short- and medium-term selling pressure, with long-term support still intact, and the nearest dynamic support located at the Ichimoku Kijun level of $27.47. Momentum on the daily chart is mixed: the MACD supports a bullish bias, while the Average Directional Index (ADX) at 17.35 is neutral, suggesting a lack of clear trend strength. The Relative Strength Index (RSI) and Commodity Channel Index (CCI) both indicate mild overbought conditions, and the Stochastic RSI sits in a neutral zone. Bull/Bear Power (BBP) is positive at 0.57, showing buyers dominate intraday, but it also indicates overbought territory. The stock is down 3.41% on the day to $26.88 after opening with a downside gap of about $0.28, trading near session lows with intraday volatility at 2.84%. Intraday indicators are broadly negative and signal pressure after the open, partly contradicting the medium-term positive momentum.

Previously it was reported that Pfizer was exhibiting sustained bullish momentum, with technical signals favoring further upside despite some short-term volatility. The latest price action introduces heightened short- and medium-term selling pressure, so traders should watch for a decisive move above $27.12 or below $26.76 to signal the next direction beyond consolidation.

Source of Data: PFE Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.